CA 15.3 is a recent tumor marker for a wide range of cancers that is usually used for monitoring breast carcinoma patients. This study was performed to evaluate CA 15.3 behaviour in 161 patients with benign diffuse hepatic diseases who underwent thorough clinical and biochemical evaluation. Abnormal serum levels of this antigen were found in 8.7% of the 161 patients, 11.6% of the 86 cirrhotics, and 5.3% of the 75 noncirrhotic patients. The correlation between CA 15.3 and certain parameters characteristic of liver diseases was checked. IgA showed the most relevant correlation (r = 0.39, p < 0.00001) and in our series a normal level of IgA was practically determinant of normal CA 15.3 levels. Our results also support the role played by hepatocellular dysfunction in increasing levels of this antigen in spite of the low number of false-positive results. CA 15.3 can be used as a tumor marker in these patients at levels used for healthy subjects.
TobiasR., RothwellC., WagnerJ., GreenA., LiuY.S.V.. Development and evaluation of a radioimmunoassay for the detection of a monoclonal antibody defined breast tumor associated antigen 115D8/DF3 (Abstract). Proceedings AACC, 1985.Clin Chem1985; 31: 986.
2.
HilkensJ., HilgersJ., BuijsF.. Monoclonal antibodies against human milkfat globule membranes useful in carcinoma research. In: PeetersH., ed. “Protides of the Biological Fluids”. Proceedings of the 31 Colloquium, 1983. Oxford: Pergamon Press, 1013–6.
3.
KufeD., InghiramiG., AbeM., HayesD., Justi-WheelerH., SchlomJ.. Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors.Hybridoma1984; 3: 223–32.
4.
VandelyP., PandianM.R.. Correlation of a mammary tumor associted antigen (CA 15-3) with steroid receptors in human mammary tumor extracts (Abstract). Proceedings AACC, 1986.Clin Chem1986; 32: 1126.
5.
GionM., MioneR., DittadiR., FasanS., PalliniA., BruscagninG.. Evaluation of CA 15/3 serum levels in breast cancer patients.J Nucl Med Allied Sci1986; 30: 29–36.
6.
GionM., MioneR., DittadiR., ZariC., BruscagninG.. CA 15-3 in breast cancer tissue (Abstract). In: GretenH., KlapdorR., eds. 4. Hamburguer Symposium über Tumormarker. 4-5 Dezember 1986.Stuttgart: Georg Thieme Verlag1986; 53.
7.
ColomerR., RuibalA., SalvadorL.. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease.Cancer1989; 64: 1674–81.
8.
Pons-AnicetD.M.F., KrebsB.P., MiraR., NamerM.. Value of CA 15: 3 in the follow-up of breast cancer patients.Br J Cancer1987; 55: 567–9.
9.
Colomer BoschR.. Utilidad clinica de la determinación sérica del antigeno asociado al cancer de mama CA 15.3. Doctoral Thesis. Universidad Autónoma de Barcelona, 1987.
10.
Schmidt-RhodeP., SchulzK.D., SturmG., Raab-FrickA., PrinzH.. CA 15.3 as a tumor marker in breast cancer.Int J Biol Markers1987; 2: 135–42.
11.
RuibalA.. CA 15.3, marcador de los cánceres mamarios.Med Clin (Bare)1988; 91: 341–3.
12.
ThirionB., RicolleauG., FumoleauP.. Result of a prospective study of the CA 15-3 reliability in early detection of breast cancer recurrence. 3rd International Workshop on Monoclonal Antibodies and Breast Cancer. San Francisco, California, November 17-18, 1988.
13.
Ruibal MorellA.. Marcadores tumorales y cancer de ovario.Rev Cancer1988; 2: 20–7.
14.
RuibalA., GenollaJ., RosellM., MoragesG., ColomerR.. CA 15-3 serum levels in oncology: clinical applications. In: GretenH., KlapdorR., eds. 4. Hamburger Symposium über Tumormarker, 4-5 Dezember 1986.Stuttgart: Georg Thieme Verlag1986; 102.
15.
TouitouY., BogdanA.. Tumor markers in nonmalignant diseases.Eur J Cancer Clin Oncol1988; 24: 1083–91.
16.
RuibalA., GenolláJ., RosellM., GrisJ.M., ColomerR.. Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients.Int J Biol Markers1986; 1: 159–60.
17.
HayesD.F., ZurawskiV.R., KufeD.W.. Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer.J Clin Oncol1986; 4: 1542–50.
18.
RuibalA., GenolláJ., RosellM., MoragasG.. El CA 15.3-ELSA serico en patologias no tumorales.Med Clin (Barc)1987; 88: 476.
19.
RuibalA., EncaboG., GenolláJ., GuargaA., UrrutiaA., ColomerR.. Serum CA 15.3 levels in patients with general pathology and malignant diseases (excluding breast cancer).Bull Cancer (Paris)1986; 73: 94–5.
20.
MolinaR., BallestaA.M., FilellaX.. Estudio de un nuevo marcador tumoral, el CA 15.3 en patologias benigna y neoplásica.Neoplasia1986; 3: 85–91.
21.
HayesD.F., SekineH., OhnoT., AbeM., KeefeK., KufeD.W.. Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients.J Clin Invest1985; 75: 1671–8.
22.
HilkensJ., KroezenV., BonfrerJ.M.G., De Jong-BakkerM., BruningP.F.. MAM-6 antigen, a new serum marker for breast cancer monitoring.Cancer Res1986; 46: 2582–7.
23.
van de WielA., van HattumJ., SchurmanH.J., KaterL.. Immunoglobulin A in the diagnosis of alcoholic liver disease.Gastroenterology1988; 94: 457–62.
